Cafedrine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cafedrine
Accession Number
DB12926
Type
Small Molecule
Groups
Investigational
Description

Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
0UYY5V4U2Q
CAS number
58166-83-9
Weight
Average: 357.414
Monoisotopic: 357.180089621
Chemical Formula
C18H23N5O3
InChI Key
UJSKUDDDPKGBJY-WFASDCNBSA-N
InChI
InChI=1S/C18H23N5O3/c1-12(15(24)13-7-5-4-6-8-13)19-9-10-23-11-20-16-14(23)17(25)22(3)18(26)21(16)2/h4-8,11-12,15,19,24H,9-10H2,1-3H3/t12-,15-/m0/s1
IUPAC Name
7-(2-{[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino}ethyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
C[C@H](NCCN1C=NC2=C1C(=O)N(C)C(=O)N2C)[C@H](O)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cafedrine.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cafedrine.
AcemetacinThe therapeutic efficacy of Cafedrine can be decreased when used in combination with Acemetacin.
AcenocoumarolThe serum concentration of Cafedrine can be increased when it is combined with Acenocoumarol.
AcetaminophenThe serum concentration of Cafedrine can be increased when it is combined with Acetaminophen.
AcetazolamideAcetazolamide may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.
AcyclovirThe serum concentration of Cafedrine can be increased when it is combined with Acyclovir.
AdalimumabThe serum concentration of Cafedrine can be decreased when it is combined with Adalimumab.
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Cafedrine.
AlbendazoleThe serum concentration of Cafedrine can be increased when it is combined with Albendazole.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5489638
PubChem Substance
347829071
ChemSpider
4590188
ChEBI
135510
Wikipedia
Cafedrine
ATC Codes
C01CA21 — Cafedrine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableArterial Hypotension1
Not AvailableWithdrawnTreatmentIschemia, Cerebral1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.56 mg/mLALOGPS
logP0.89ALOGPS
logP0.6ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)9.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.7 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity97.55 m3·mol-1ChemAxon
Polarizability37.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Xanthines
Alternative Parents
6-oxopurines / Phenylpropanes / Alkaloids and derivatives / Pyrimidones / Aralkylamines / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Ureas / Secondary alcohols
show 7 more
Substituents
Xanthine / 6-oxopurine / Purinone / Phenylpropane / Alkaloid or derivatives / Pyrimidone / Aralkylamine / Benzenoid / Monocyclic benzene moiety / Pyrimidine
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:21 / Updated on October 01, 2018 15:22